특집 : 진행성 노인 대장암에 대한 항암요법

作者: Hye Sook Han

DOI: 10.3904/KJM.2014.87.5.530

关键词:

摘要: Colorectal cancer (CRC) affects largely elderly populations. However, older patients with CRC are generally excluded from randomized clinical trials, and the healthy subjects who recruited not representative of general patient population. Nevertheless, recent data trials specifically targeting related subgroup analyses indicate that well-selected can have a similar response to younger patients. Chronological age should determine candidacy for adjuvant or palliative chemotherapy in CRC. The appropriate management would mean they could receive aggressive regimen patients, whereas care frail those short life expectancy focus on palliation. use comprehensive geriatric assessment allow safe beneficial regimens (Korean J Med 2014;87:530-536)

参考文章(27)
Daniel J. Sargent, Richard M. Goldberg, Stacy D. Jacobson, John S. Macdonald, Roberto Labianca, Daniel G. Haller, Lois E. Shepherd, Jean François Seitz, Guido Francini, A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients. The New England Journal of Medicine. ,vol. 345, pp. 1091- 1097 ,(2001) , 10.1056/NEJMOA010957
Rosemary Yancik, Population aging and cancer : A cross-national concern Cancer Journal. ,vol. 11, pp. 437- 441 ,(2005) , 10.1097/00130404-200511000-00002
Jean-Yves Douillard, Kelly S Oliner, Salvatore Siena, Josep Tabernero, Ronald Burkes, Mario Barugel, Yves Humblet, Gyorgy Bodoky, David Cunningham, Jacek Jassem, Fernando Rivera, Ilona Kocákova, Paul Ruff, Maria Błasińska-Morawiec, Martin Šmakal, Jean Luc Canon, Mark Rother, Richard Williams, Alan Rong, Jeffrey Wiezorek, Roger Sidhu, Scott D Patterson, None, Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer The New England Journal of Medicine. ,vol. 369, pp. 1023- 1034 ,(2013) , 10.1056/NEJMOA1305275
G. Folprecht, D. Cunningham, P. Ross, B. Glimelius, F. Di Costanzo, J. Wils, W. Scheithauer, P. Rougier, E. Aranda, H. Hecker, C.-H. Köhne, Efficacy of 5-fluorouracil-based chemotherapy in elderly patients with metastatic colorectal cancer: a pooled analysis of clinical trials Annals of Oncology. ,vol. 15, pp. 1330- 1338 ,(2004) , 10.1093/ANNONC/MDH344
Howard S. Hochster, Lowell L. Hart, Ramesh K. Ramanathan, Barrett H. Childs, John D. Hainsworth, Allen L. Cohn, Lucas Wong, Louis Fehrenbacher, Yousif Abubakr, M. Wasif Saif, Lee Schwartzberg, Eric Hedrick, Safety and Efficacy of Oxaliplatin and Fluoropyrimidine Regimens With or Without Bevacizumab As First-Line Treatment of Metastatic Colorectal Cancer: Results of the TREE Study Journal of Clinical Oncology. ,vol. 26, pp. 3523- 3529 ,(2008) , 10.1200/JCO.2007.15.4138
James Cassidy, Leonard B. Saltz, Bruce J. Giantonio, Fairooz F. Kabbinavar, Herbert I. Hurwitz, Ulrich-Peter Rohr, Effect of bevacizumab in older patients with metastatic colorectal cancer: pooled analysis of four randomized studies. Journal of Cancer Research and Clinical Oncology. ,vol. 136, pp. 737- 743 ,(2010) , 10.1007/S00432-009-0712-3
M.J. Sorich, M.D. Wiese, A. Rowland, G. Kichenadasse, R.A. McKinnon, C.S. Karapetis, Extended RAS mutations and anti-EGFR monoclonal antibody survival benefit in metastatic colorectal cancer: a meta-analysis of randomized, controlled trials Annals of Oncology. ,vol. 26, pp. 13- 21 ,(2015) , 10.1093/ANNONC/MDU378